GI 254023X: Precision Inhibition of ADAM10 Metalloprotease in Translational Research

Executive Summary: GI 254023X is a potent and selective inhibitor of ADAM10, exhibiting an IC₅₀ of 5.3 nM and >100-fold selectivity versus ADAM17, which enables targeted modulation of sheddase activity in diverse biological contexts (APExBIO). It blocks ADAM10-mediated cleavage of key substrates such as fractalkine (CX3CL1) and VE-cadherin, impacting Notch1 signaling and endothelial barrier integrity (PrecisionFDA). In vitro, GI 254023X induces apoptosis in Jurkat T-lymphoblastic leukemia cells and prevents Staphylococcus aureus α-hemolysin-induced endothelial disruption (Cadherin-Peptide). In vivo, a regimen of 200 mg/kg/day intraperitoneally for 3 days in BALB/c mice was shown to enhance vascular integrity and survival after lethal bacterial toxin challenge (APExBIO). GI 254023X is a research-use-only reagent, supplied as a white solid (MW 391.5, C₂₁H₃₃N₃O₄), insoluble in water but readily soluble in DMSO or ethanol.

Biological Rationale

ADAM10 (A Disintegrin and Metalloproteinase domain-containing protein 10, EC 3.4.24.81) is a membrane-anchored metalloprotease with broad peptide hydrolysis specificity. It functions as a sheddase for diverse substrates, including fractalkine (CX3CL1), Notch receptors, and VE-cadherin, mediating key steps in cell-cell adhesion, signaling, and immune modulation (Satir et al., 2020). Aberrant ADAM10 activity is implicated in cancer, neurodegeneration, and vascular pathologies. Inhibition of ADAM10 offers a targeted tool to dissect these pathways and clarify the distinct roles of metalloprotease subtypes in physiology and disease. A critical distinction is drawn between ADAM10 and related proteases such as ADAM17 and β-secretase (BACE1), as broad-spectrum inhibition can lead to off-target effects or misinterpretation of mechanistic data (Strategic Inhibition of ADAM10 with GI 254023X—this article provides deeper mechanistic contrast with BACE inhibition for neurodegeneration research).

Mechanism of Action of GI 254023X

GI 254023X, developed and distributed by APExBIO, is a low molecular weight, non-peptidic inhibitor designed to bind the catalytic site of ADAM10 with nanomolar potency (IC₅₀ = 5.3 nM in biochemical assays at 25°C, pH 7.5, buffer containing 50 mM Tris-HCl). It demonstrates over 100-fold selectivity against ADAM17 and does not inhibit BACE1 or γ-secretase at concentrations up to 10 μM (product page). Mechanistically, GI 254023X blocks the proteolytic cleavage of cell surface substrates by ADAM10, preventing the release of functional ectodomains. This includes inhibition of constitutive fractalkine (CX3CL1) cleavage, disruption of Notch1 receptor activation, and prevention of VE-cadherin processing in endothelial cells (GI 254023X: Transforming Endothelial Barrier & Leukemia Models—this article extends the mechanistic depth by detailing downstream effects on apoptosis and barrier function).

Evidence & Benchmarks

• GI 254023X inhibits human ADAM10 enzyme activity with an IC₅₀ of 5.3 nM under standard in vitro assay conditions (25°C, pH 7.5, Tris buffer) (APExBIO).
• Displays >100-fold selectivity over ADAM17, minimizing off-target metalloprotease inhibition (APExBIO).
• Blocks constitutive cleavage of fractalkine (CX3CL1) and suppresses Notch1 activation in Jurkat T-lymphoblastic leukemia cells, reducing levels of cleaved Notch1, MCL-1, and Hes-1 mRNAs (in vitro, 1–10 μM, 24–48 h) (Strategic Inhibition of ADAM10 with GI 254023X).
• Induces apoptosis and inhibits proliferation in Jurkat cells as measured by flow cytometry and qPCR (1–10 μM, 48 h exposure) (GI 254023X: Transforming Endothelial Barrier & Leukemia Models).
• Prevents Staphylococcus aureus α-hemolysin-induced cleavage of VE-cadherin and protects endothelial barrier integrity in human pulmonary artery endothelial cells (HPAECs) (pre-treatment with 10 μM GI 254023X, 37°C, 2 h) (Satir et al., 2020).
• In vivo, intraperitoneal administration of 200 mg/kg/day for 3 days in BALB/c mice enhances vascular integrity and improves survival after lethal toxin challenge (APExBIO).

Applications, Limits & Misconceptions

GI 254023X enables targeted interrogation of ADAM10-dependent pathways in cancer, acute T-lymphoblastic leukemia, endothelial barrier disruption, and vascular biology. Comparative analysis with BACE1 inhibitors demonstrates that ADAM10 inhibition allows for selective modulation of non-amyloidogenic pathways, avoiding global reduction of amyloid-β production that can impair synaptic function if not precisely controlled (Satir et al., 2020). For a scenario-driven guide to optimizing assay reliability and vendor selection, see GI 254023X (SKU A4436): Scenario-Driven Solutions for ADAM10 Inhibition, which this article updates by detailing new data on apoptosis and in vivo vascular protection.

Common Pitfalls or Misconceptions

• GI 254023X is ineffective against ADAM17, BACE1, or γ-secretase at research-relevant concentrations (<10 μM); it should not be used as a pan-metalloprotease inhibitor (APExBIO).
• Compound is insoluble in water; use DMSO (≥42.6 mg/mL) or ethanol (≥46.1 mg/mL) for stock solutions. Improper solvent use leads to precipitation and data artifacts.
• Long-term storage of solutions at room temperature or repeated freeze-thaw cycles degrades potency. Stocks should be stored at -20°C and used promptly after dilution (APExBIO).
• Results from mouse or cell models may not fully translate to human clinical settings; GI 254023X is for research use only, not for diagnostic or therapeutic application.
• Not a substitute for BACE inhibition in amyloid-β pathway studies; use only when ADAM10-specific effects are desired (Satir et al., 2020).

Workflow Integration & Parameters

GI 254023X is supplied as a white solid (MW 391.5; C₂₁H₃₃N₃O₄) and is intended for laboratory research. For in vitro work, prepare stock solutions in DMSO or ethanol at concentrations >10 mM, using gentle warming and sonication to enhance solubility. Standard working concentrations range from 1–10 μM for cell-based assays, with 24–72 h incubation at 37°C. For in vivo studies, intraperitoneal dosing at 200 mg/kg/day for 3 consecutive days in BALB/c mice maintains plasma levels sufficient to inhibit ADAM10 activity and demonstrate vascular protection. Avoid freeze-thaw cycles and store stocks at -20°C. See the product page (GI 254023X) for detailed handling and storage protocols.

Conclusion & Outlook

GI 254023X (SKU A4436) is a rigorously characterized, selective ADAM10 inhibitor provided by APExBIO for precision research applications. Its nanomolar potency, high selectivity, and validated efficacy in both cell and mouse models position it as a preferred reagent for dissecting ADAM10-mediated signaling, vascular biology, and leukemia cell survival. When integrated into workflows with attention to solubility, storage, and model selection, GI 254023X enables reproducible, mechanistically precise experimentation. Future research may expand its utility into additional disease models, provided its boundaries and specificity are respected. For deeper mechanistic context and protocol recommendations, see GI 254023X: Selective ADAM10 Inhibitor for Vascular and Leukemia Models, which this article updates with expanded evidence on in vivo protection and workflow integration.